Tesamorelin Research for HIV Lipodystrophy
An evidence-based overview of research examining Tesamorelin in the context of hiv lipodystrophy. This page synthesizes findings from peer-reviewed literature.
Research Summary
Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy, making it one of the few peptides with regulatory approval for a defined medical condition. Phase 3 trials demonstrated significant reduction in visceral adipose tissue (VAT) with a mean difference of -27.7 cm² compared to placebo.
The pooled analysis of pivotal trials (n=806) showed consistent efficacy across multiple endpoints including trunk fat reduction, IGF-1 normalization, and metabolic improvements. The mechanism addresses the reduced GH secretion and GH pulse amplitude seen in HIV patients on antiretroviral therapy.
Long-term extension data confirm durability of effects with continued treatment, though VAT returns to near-baseline within weeks of discontinuation, requiring chronic therapy for maintained benefits.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for HIV Lipodystrophy
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Tesamorelin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.